Kevin Hollevoet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kevin Hollevoet has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Jan P. van Meerbeeck
Antwerp University Hospital, Edegem, Belgium
2 shared publications Alex J. Rai
1 shared publicationAlfonso Cristaudo
1 shared publicationAnja Van Den Eeckhaut
Nuclear Medicine, AZ Sint-Jan AV, Bruges, Belgium, Departments of
1 shared publicationArnaud Scherpereel
1 shared publicationBogdan D. Grigoriu
1 shared publication
Latest Publications
- 10 January 2013
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 368 (2) , 189-190
Fibulin-3 as a Biomarker for Pleural Mesothelioma
To the Editor: Pass et al. (Oct. 11 issue)1 report on fibulin-3 as a new soluble biomarker for malignant mesothelioma. The diagnostic accuracy of plasma levels of fibulin-3 in the Detroit and New York cohorts (area under the receiver-operating-characteristic curve [AUC], 0.99) exceeded that of any previously reported marker. In the external validation cohort, however, the diagnostic accuracy surprisingly decreased (AUC, 0.87). This marked decrease was probably due to differences in the study population, although the study showed no association between plasma fibulin-3 levels and common patient characteristics. To fully comprehend the potential and limitations of this new biomarker, researchers . . .
- 10 January 2013
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 368 (2) , 189-190
Fibulin-3 as a Biomarker for Pleural Mesothelioma
To the Editor: Pass et al. (Oct. 11 issue)1 report on fibulin-3 as a new soluble biomarker for malignant mesothelioma. The diagnostic accuracy of plasma levels of fibulin-3 in the Detroit and New York cohorts (area under the receiver-operating-characteristic curve [AUC], 0.99) exceeded that of any previously reported marker. In the external validation cohort, however, the diagnostic accuracy surprisingly decreased (AUC, 0.87). This marked decrease was probably due to differences in the study population, although the study showed no association between plasma fibulin-3 levels and common patient characteristics. To fully comprehend the potential and limitations of this new biomarker, researchers . . .
- 1 May 2012
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (13) , 1541-1549
Serum Mesothelin for Diagnosing Malignant Pleural Mesothelioma: An Individual Patient Data Meta-Analysis
Purpose: Mesothelin is currently considered the best available serum biomarker of malignant pleural mesothelioma. To examine the diagnostic accuracy and use of serum mesothelin in early diagnosis, we performed an individual patient data (IPD) meta-analysis. Methods: The literature search identified 16 diagnostic studies of serum mesothelin, measured with the Mesomark enzyme-linked immunosorbent assay. IPD of 4,491 individuals were collected, including several control groups and 1,026 patients with malignant pleural mesothelioma. Mesothelin levels were standardized for between-study differences and age, after which the diagnostic accuracy and the factors affecting it were examined with receiver operating characteristic (ROC) regression analysis. Results: At a common diagnostic threshold of 2.00 nmol/L, the sensitivities and specificities of mesothelin in the different studies ranged widely from 19% to 68% and 88% to 100%, respectively. This heterogeneity can be explained by differences in study population, because type of control group, mesothelioma stage, and histologic subtype significantly affected the diagnostic accuracy. The use of mesothelin in early diagnosis was evaluated by differentiating 217 patients with stage I or II epithelioid and biphasic mesothelioma from 1,612 symptomatic or high-risk controls. The resulting area under the ROC curve was 0.77 (95% CI, 0.73 to 0.81). At 95% specificity, mesothelin displayed a sensitivity of 32% (95% CI, 26% to 40%). Conclusion: In patients suspected of having mesothelioma, a positive blood test for mesothelin at a high-specificity threshold is a strong incentive to urge further diagnostic steps. However, the poor sensitivity of mesothelin clearly limits its added value to early diagnosis and emphasizes the need for further biomarker research.
- 1 May 2012
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (13) , 1541-1549
Serum Mesothelin for Diagnosing Malignant Pleural Mesothelioma: An Individual Patient Data Meta-Analysis
Purpose: Mesothelin is currently considered the best available serum biomarker of malignant pleural mesothelioma. To examine the diagnostic accuracy and use of serum mesothelin in early diagnosis, we performed an individual patient data (IPD) meta-analysis. Methods: The literature search identified 16 diagnostic studies of serum mesothelin, measured with the Mesomark enzyme-linked immunosorbent assay. IPD of 4,491 individuals were collected, including several control groups and 1,026 patients with malignant pleural mesothelioma. Mesothelin levels were standardized for between-study differences and age, after which the diagnostic accuracy and the factors affecting it were examined with receiver operating characteristic (ROC) regression analysis. Results: At a common diagnostic threshold of 2.00 nmol/L, the sensitivities and specificities of mesothelin in the different studies ranged widely from 19% to 68% and 88% to 100%, respectively. This heterogeneity can be explained by differences in study population, because type of control group, mesothelioma stage, and histologic subtype significantly affected the diagnostic accuracy. The use of mesothelin in early diagnosis was evaluated by differentiating 217 patients with stage I or II epithelioid and biphasic mesothelioma from 1,612 symptomatic or high-risk controls. The resulting area under the ROC curve was 0.77 (95% CI, 0.73 to 0.81). At 95% specificity, mesothelin displayed a sensitivity of 32% (95% CI, 26% to 40%). Conclusion: In patients suspected of having mesothelioma, a positive blood test for mesothelin at a high-specificity threshold is a strong incentive to urge further diagnostic steps. However, the poor sensitivity of mesothelin clearly limits its added value to early diagnosis and emphasizes the need for further biomarker research.
- 1 July 2009
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 55 (7) , 1431-1433
Glomerular Filtration Rate Is a Confounder for the Measurement of Soluble Mesothelin in Serum
We enrolled 66 individuals (49 men and 17 women; median age, 58 years; range, 24–80 years), who were referred for measurement of 51Cr-EDTA clearance to estimate the GFR. We excluded patients with asbestos-related diseases/malignancies, patients with endometrial, ovarian, cervix, lung, breast, pancreatic, or gastrointestinal cancer, and patients with leukemia, because these conditions can overexpress mesothelin (3)(4). The study was approved by the ethics committee of both participating hospitals, and participants gave written informed consent. In addition, we analyzed GFR data from 51 chemotherapy-naive mesothelioma patients (47 men and 4 women; median age, 63 years; range, 45–79 years) who had undergone treatment at our institution between 2003 and 2008.
- 1 July 2009
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 55 (7) , 1431-1433
Glomerular Filtration Rate Is a Confounder for the Measurement of Soluble Mesothelin in Serum
We enrolled 66 individuals (49 men and 17 women; median age, 58 years; range, 24–80 years), who were referred for measurement of 51Cr-EDTA clearance to estimate the GFR. We excluded patients with asbestos-related diseases/malignancies, patients with endometrial, ovarian, cervix, lung, breast, pancreatic, or gastrointestinal cancer, and patients with leukemia, because these conditions can overexpress mesothelin (3)(4). The study was approved by the ethics committee of both participating hospitals, and participants gave written informed consent. In addition, we analyzed GFR data from 51 chemotherapy-naive mesothelioma patients (47 men and 4 women; median age, 63 years; range, 45–79 years) who had undergone treatment at our institution between 2003 and 2008.